Comera Life Sciences
Enhancing therapeutic protein formulations for better patient experience and extended product lifecycle.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor investor | €0.0 | round | |
| investor | €0.0 Valuation: €0.0 239.0x EV/Revenue -11.3x EV/EBITDA | round | |
| investor investor investor investor investor | €0.0 | round | |
* | N/A | $4.1m | Private Placement VC |
| Total Funding | 000k | ||
| USD | 2020 | 2021 | 2022 |
|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 |
| % growth | - | (28 %) | 98 % |
| EBITDA | 0000 | 0000 | 0000 |
| % EBITDA margin | (460 %) | (1754 %) | (2106 %) |
| Profit | 0000 | 0000 | 0000 |
| % profit margin | (480 %) | (1705 %) | (2844 %) |
| EV | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 |
| R&D % of revenue | 285 % | 548 % | 275 % |
Source: Company filings or news article
Related Content
Comera Life Sciences operates in the life sciences sector, focusing on transforming intravenous (IV) biologics into subcutaneous (SQ) self-administered injections. This innovation aims to provide patients with the freedom to administer their own medication, reducing the need for time-consuming and costly visits to infusion centers. The company serves patients with significant diseases who rely on biologic therapeutics, offering them a more convenient and less painful treatment option. Comera's business model revolves around developing and commercializing these self-injectable biologics, generating revenue through product sales and potential partnerships with pharmaceutical companies. By leveraging their proprietary platform, Comera aims to maximize the therapeutic potential of biologics, ultimately improving patient outcomes and quality of life.
Keywords: biologics, self-injection, patient care, life sciences, innovation, therapeutics, convenience, healthcare, medical technology, infusion alternatives.